Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has shared an announcement.
Clover Biopharmaceuticals, Ltd. has scheduled a board meeting for March 25, 2026 to review and approve the annual results for the year ended December 31, 2025, and to consider the publication of those results. The board will also deliberate on whether to recommend a final dividend, a decision that could affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also confirms the current composition of Clover’s board, which includes executive, non-executive and independent non-executive directors led by chairman Dr. Peng Liang. This governance disclosure underscores the company’s compliance with Hong Kong listing requirements and provides investors with transparency on the leadership overseeing its strategic and financial decisions.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd. is a biotechnology company listed on the Hong Kong Stock Exchange, focused on developing and commercializing biopharmaceutical products. The company operates through its subsidiaries and is governed by a board comprising executive, non-executive and independent non-executive directors with scientific and financial expertise.
Average Trading Volume: 3,958,414
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.84B
For a thorough assessment of 2197 stock, go to TipRanks’ Stock Analysis page.